11 investors predict a colorful, if difficult, future for psychedelic startups
TechCrunch
MAY 12, 2023
In the meantime, pharma and big biotech VC firms are more interested in exploring the non-hallucinogenic psychedelic pathways. Whether developing a drug or not, a company would be attractive to investors if and only if it is addressing a key problem in the market that cannot already be solved by incumbents efficiently.
99 
Let's personalize your content